Shionogi & Co., Ltd. · TSE:4507
Shionogi & — Shareholder Meeting (June 2022)
22 slides from Shionogi &'s shareholder meeting presentation, June 2022
Slide 1: The 157th Business Report
The 157th Business Report from April 1, 2021 to March 31, 2022.
Slide 2: Current State of the Shionogi Group
Current State of the Shionogi Group 2
Slide 3: Vision 2030 and New Medium-Term Business Plan STS2030
Vision 2030 and New Medium-Term Business Plan “STS2030“ Vision 2030 Strategy to achieve 2030 Vision Building Innovation Platforms to Shape the Future of Healthcare STS2030 - Shionogi Transformation Strategy 2030 - STS2030 STS Phase1 (’20-’24) STS Phase2 (’25-) 3
Slide 4: Total Care for Infectious Diseases - Actions for early termination of COVID-19
Total Care for Infectious Diseases - Actions for the early termination of COVID-19 - Epidemic Exacerbation Prevention Diagnosis Treatment forecasting suppression Launch of sewage Provision of quick Development of epidemiology Development of Development of and easy-to-use Asapiprant surveillance surv
Slide 5: Business Operations and Results
Business Operations and Results 5
Slide 6: Financial Results (Consolidated) - Revenue
① Financial Results (Consolidated) - Revenue - Revenue by segment （B yen） Revenue FY2020 FY2021 Up 12.8% YoY Prescription drugs 94.7 89.1 （B yen） Overseas subsidiaries/ 24.6 34.4 297.2 335.1 export Contract manufacturing 19.7 17.4 OTC and quasi- drug 11.7 11.2 FY2020 FY2021 Royalty income 144.6 181.
Slide 7: Financial Results (Consolidated) - Each profit
① Financial Results (Consolidated) - Each profit - Operating Core operating Profit Profit attributable to Profit profit before tax owners of parent Down 6.1% YoY Up 17.7% YoY Down 11.7% YoY Up 2.1% YoY （B yen） （B yen） （B yen） （B yen） 117.4 110.3 94.0 110.6 143.0 126.3 111.9 114.2 FY2020 FY2021 FY202
Slide 8: Financial Results (Consolidated) - Assets, etc.
① Financial Results (Consolidated) – Assets, etc. - • Maintain a stable financial base • Progress in efforts to improve corporate value over the medium to long term Items of consolidated statement of financial position （B yen） Y on Y FY2020 FY2021 Change (%） Total assets 999.0 1,150.6 15.2% Total eq
Slide 9: Royalties and Dividend Income From ViiV
② Royalties and Dividend Income From ViiV Royalties and dividend income from the HIV franchise stably increased ■ Royalty income from others and transient 194.2B yen (Up 15.6% YoY) milestones (including income from Roche) 168.0B yen ■ Royalty income from AstraZeneca ③ ② ■ Royalty incomes and dividen
Slide 10: Domestic Business
③ Domestic Business • Decrease in sales of prescription drugs (Down 5.9% YoY) • Increase in sales of Intuniv and Vyvanse Sales trends of core products (Cymbalta, anti-infection drugs, ADHD franchise) 49.6B yen 44.9B yen (Down 9.5% YoY) ■ Decrease in sales of Cymbalta: Down39.9% YoY Cymbalta Influenz
Slide 11: Overseas Business - Maximize the value of Cefiderocol
③ Overseas Business - Maximize the value of Cefiderocol (Fetroja/Fetcroja)* - • Increased sales of cefiderocol in the US and Europe • China: Progress toward building a new business model by Ping An-Shionogi US, EU: Increase in sales of cefiderocol China: Increase in sales (Up 1.1％ YoY) 6.2B yen In
Slide 12: R&D
④ R&D Accelerate the R&D of growth drivers by leveraging the speed gained from the COVID-19 experience Core project Project Indication Project Indication S-217622 COVID-19 treatment S-600918 Psycho‐ Refractory chronic cough neurologi [sivopixant] cal S-268019 COVID-19 vaccine S-812217 diseases Depre
Slide 13: Manufacture and supply chain
⑤ Manufacture and supply chain • Launched production of COVID-19 therapeutic drug and vaccine • Started a business utilizing high potency pharmaceuticals and a continuous manufacturing technology as a pillar of the CDMO* business * CDMO : Contract Development Manufacturing Organization Production o
Slide 14: Challenges Ahead
for youl_/) Challenges Ahead @® SHIONOGI
Slide 15: Issues to be addressed and Review of FY2021
Issuess to be addressed and Review of FY2021 Challenges to be addressed for sustainable growth Results for the current period Early commercialization of COVID-19 therapeutic and Achieved forecasts vaccines Strengthening Progress of Sophistication Development of domestic/overseas COVID-19 related and
Slide 16: Action for COVID-19 in FY2022 - Therapeutic drug
Action for COVID-19 in FY2022 - Therapeutic drug - R&D of therapeutic drug S-217622 • Cooperation with Japanese regulatory authority for provision in Japan Domestic manufacturing and marketing approval Start domestic supply • Cooperation with regulatory authorities in each country for global pro
Slide 17: Action for COVID-19 in FY2022 - Vaccine
Action for COVID-19 in FY2022 - Vaccine - R&D of recombinant protein vaccine S-268019 • Cooperation with Japanese regulatory authority for provision in Japan Domestic manufacturing and marketing approval Start domestic supply • Cooperation with regulatory authorities in each country for global p
Slide 18: Dividend Policy
for youl_/) Dividend Policy @® SHIONOGI
Slide 19: Plan to increase dividend for the tenth consecutive year
Shareholder return policy through which shareholders can feel our growth Plan to increase dividend for （yen） the ten consecutive year 150 115 120 （planned）（planned） 103 108 100 94 82 72 60 62 55 46 52 50 53 （planned） 50 42 34 38 44 22 24 28 20 0 FY 12 13 14 15 16 17 18 19 20 21 22 Buyback - - 30 B y
Slide 20: 2030 Vision - Building Innovation Platforms to Shape the Future of Healthcare
2030 Vision - What we want to achieve by 2030 - Building Innovation Platforms to Shape the Future of Healthcare 20
Slide 21: SHIONOGI: New Brand Launch (from Jul. 1st, 2022)
SHIONOGI: New Brand Launch（from Jul. 1st, 2022） SHIONOGI will grow into a company that can contribute globally to solving social issues Regaining the safety and security of society as "SHIONOGI, a leading company of infectious disease“ Pursuing innovation and constantly challenging to shape the futu
Slide 22: Forward-Looking Statements
Forward-Looking Statements Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclos